Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NeuroSearch A/S
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson"s disease according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria

• Levodopa induced dyskinesia

Exclusion Criteria:

• Previous surgery for Parkinson's disease

• Any current or history of heart condition or increased pro-arrhythmic risk

• Severe or ongoing unstable medical condition